Tenon Medical demonstrated robust growth in Q3 2025, achieving record revenues of $1.2 million, a 32% increase year-over-year, driven by high demand for its innovative sacroiliac joint fusion solutions.

• Successful integration of CyVantage's Symmetry portfolio contributed to top-line growth, marking a pivotal point in Tenon’s strategic expansion.
• Full commercial launch of the Catamaran SE system showcased enhanced functionality, addressing varied patient needs and improving competitive positioning.
• Positive clinical outcomes from the ongoing main sales study further validated the efficacy of the Catamaran system, with statistically significant improvements in patient pain and disability scores.
• Tenon received FDA 510(k) clearance for the Symmetry Plus system, enhancing its product offerings and preparing for the upcoming alpha launch.
• Cash position remained strong at $3.4 million with no debt, supplemented by a recent $2.85 million investment.